<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284920</url>
  </required_header>
  <id_info>
    <org_study_id>9785-CL-0111</org_study_id>
    <nct_id>NCT01284920</nct_id>
  </id_info>
  <brief_title>A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients</brief_title>
  <official_title>A Phase I/II, Open-Label, Uncontrolled, Dose-Escalation Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate safety, tolerability pharmacokinetics and efficacy of MDV3100 after
      oral administration to patients with castration-resistant prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase1/2, open-label, uncontrolled study, involving Dose-Escalation Cohorts, where
      dose will be escalated to next dose with the safety, tolerability, and PK being evaluated in
      metastatic castration-resistant prostate cancer (mCRPC) patients and an Expansion Cohort,
      where the efficacy, safety, and PK of MDV3100 in post-chemo mCRPC patients will be evaluated.
      After evaluation of the safety and tolerability in Dose-Escalation Cohorts, additional
      patients are included in Expansion Cohort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by the vital signs, incidence of adverse events, labo-tests and 12-lead EGC</measure>
    <time_frame>3 months during the study</time_frame>
    <description>This measure will be assessed on the dose escalation cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response assessed by Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Day 85 and end of long term dosing period</time_frame>
    <description>This measure will be assessed on the dose expansion cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA) Response</measure>
    <time_frame>Day 85 and end of long term dosing period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the vital signs, incidence of adverse events, labo-tests and 12-lead ECG</measure>
    <time_frame>3 months during the study</time_frame>
    <description>This measure will be assessed on the dose expansion cohort.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Prostate Neoplasms</condition>
  <condition>Prostate Cancer</condition>
  <condition>Castration Resistant Prostate Cancer (CRPC)</condition>
  <arm_group>
    <arm_group_label>dose-escalation cohort-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDV3100 low dose arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose-escalation cohort-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDV3100 middle dose arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose-escalation cohort-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDV3100 high dose arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose-expansion cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose expansion with MDV3100 middle dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDV3100</intervention_name>
    <description>oral</description>
    <arm_group_label>dose-escalation cohort-1</arm_group_label>
    <arm_group_label>dose-escalation cohort-2</arm_group_label>
    <arm_group_label>dose-escalation cohort-3</arm_group_label>
    <arm_group_label>dose-expansion cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Ongoing androgen deprivation therapy with a GnRH analogue or a bilateral orchiectomy

          -  Progressive disease after prior androgen deprivation therapy (medical or surgical
             castration)

          -  For Expansion Cohort, the patient has no more than two prior chemotherapy regimens
             with at least one regimen containing docetaxel

          -  For Expansion Cohort, the patient must have measurable lesions by RECIST

        Exclusion Criteria:

          -  Metastases in the brain

          -  History of another malignancy except for adenocarcinoma of the prostate within the
             previous 5 years

          -  Use of bicalutamide within 6 weeks prior to study

          -  Radiation therapy within 12 weeks prior to study

          -  Evidence of serious drug hypersensitivity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 150714 in the JapicCTI-RNo. field</description>
  </link>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=9785-CL-0111</url>
    <description>Link to results on Astellas Clinical Study Results Web site</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDV3100</keyword>
  <keyword>Response Evaluation Criteria in Solid Tumor (RECIST)</keyword>
  <keyword>docetaxel</keyword>
  <keyword>PSA level</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

